IL28B Genotype on HCV Infection in Asia

Liu, Chen–Hua; Kao, Jia‐Horng

doi:10.1007/s11901-013-0176-4

Cited by 3 publications

(2 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In hepatitis C virus (HCV) infection control, human interleukin 28B (IL-28B) genetics may play a role in patients' selection and treatment decisions. The most common IL-28B single-nucleotide polymorphisms (SNPs) are rs8099917 and rs12979860, which are associated with spontaneous clearance or sustained viral response with interferon treatment of HCV genotype 1 [ 1 , 2 ]. Patients with the favourable rs12979860 CC genotype show better treatment responses, particularly among Asians [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Identification of IL-28B Genotype Modification in Hepatocytes after Living Donor Liver Transplantation by Laser Capture Microdissection and Pyrosequencing Analysis

Chiu

Nakano

Chen

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

The aim of this study is to elucidate the biogenetic modification of donor and recipient interleukin-28B (IL-28B) genotypes in liver graft biopsies after living donor liver transplantation (LDLT) for chronic hepatitis C virus- (HCV-) related, end-stage liver disease. Fifty liver graft biopsies were collected from recipients during LDLT treatment for HCV-related, end-stage liver disease. DNA was extracted from all 50 liver tissues, and the IL-28B single-nucleotide polymorphisms (SNPs) rs8099917 and rs12979860 were studied for allelic discrimination by real-time PCR analysis. Blood samples were obtained from donors and recipients on postoperative day 0 (POD0), POD7, and POD30. We randomly selected five liver biopsies and isolated the hepatocytes by laser capture microdissection (LCM) to evaluate genotype modifications resulting from LDLT. After LDLT, the IL-28B SNP rs8099917 was identified not only in the liver graft biopsies and donors' sera (TT = 41 : 43; GT = 9 : 5; GG = 0 : 2), but also in liver graft biopsies and recipients' sera on POD0 (TT = 41 : 44; GT = 9 : 4; GG = 0 : 2), POD7 (TT = 41 : 30; GT = 9 : 18; GG = 0 : 2), and POD30 (TT = 41 : 29; GT = 9 : 19; GG = 0 : 2). A significant difference was observed between the rs8099917 allele frequencies of liver graft biopsies and recipients' sera on POD30 (p = 0.039). In addition, a significant difference was also noted between the rs12979860 allele frequencies of liver graft biopsies and donors' sera (CT = 49 : 39; TT = 1 : 10) (p = 0.012) and of liver graft biopsies and recipients' sera on POD0 (CT = 49 : 39; TT = 1 : 11) (p = 0.002), POD7 (CT = 49 : 42; TT = 1 : 8) (p = 0.016), and POD30 (CT = 49 : 41; TT = 1 : 9) (p = 0.008). This phenomenon was confirmed by pyrosequencing of hepatocytes isolated by LCM. Following LDLT, the TT-to-GT IL-28B genotype modification predominated in rs8099917, and the CC-to-CT modification predominated in rs12979860. In conclusion, these modified phenomena suggested that the selected donor with a predictable and favourable IL-28B genotype will not confer a benefit on the recipient in the living donor liver transplantation setting.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of IL-28B Genotype Modification in Hepatocytes after Living Donor Liver Transplantation by Laser Capture Microdissection and Pyrosequencing Analysis

Chiu

Nakano

Chen

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…The higher response rate in Asian HCV-1 patients than in Western patients was explained by the discovery of human interleukin-28B (IL-28B) genetic polymorphisms (rs12979860 or rs8099917) that strongly affect the SVR rates in HCV-1 patients receiving dual therapy of PEG-IFN α plus RBV. 10,11 Recently, the development of telaprevir (TVR) or boceprevir (BOC)-based triple therapy with PEG-IFN α plus RBV further improved the SVR rate to 66%-76% in treated and untreated HCV-1 patients and has become the standard of care (SOC) for Western HCV-1 patients. [12][13][14][15] Many novel direct-acting antiviral agents (DAAs), either in combination with PEG-IFN α plus RBV or used as IFN-free regimens are under active investigation.…”

mentioning

confidence: 99%

Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa

Liu¹,

Kao

2014

IJN

Self Cite

View full text Add to dashboard Cite

Asia is endemic for hepatitis C virus (HCV) infection, which is the leading cause of cirrhosis, hepatic decompensation, hepatocellular carcinoma, and liver transplantation worldwide. HCV has six major genotypes and each HCV genotype has its specific geographic distribution. HCV genotypes 1, 2, 3, and 6 are common in Asia. The aim of HCV treatment is to eradicate the virus by effective therapeutic agents; viral clearance is durable after long-term post-treatment follow-up. In most Asian countries, peginterferon alfa (PEG-IFN α) in combination with ribavirin remains the standard of care, and the overall sustained viral response (SVR) rate in Asian HCV patients is higher than that in Western patients. The differences are most significant in patients with HCV genotype 1 (HCV-1) infection, which is attributed to the higher frequency of IFN-responsive or favorable interleukin-28B (IL-28B) genotype in Asian populations than in other ethnic populations. In addition, the introduction of response-guided therapy, where the optimized treatment duration is based on the early viral kinetics during the first 12 weeks of treatment, increases the SVR rate. Recently, telaprevir or boceprevir-based triple therapy was found to further improve the SVR rate in treated and untreated HCV-1 patients and has become the new standard of care in Western and some Asian countries. Many novel direct-acting antiviral agents, either in combination with PEG-IFN α plus ribavirin or used as IFN-free regimens are under active investigation. At the time of this writing, simeprevir and sofosbuvir have been approved in the US. Because the SVR rates in Asian HCV patients receiving PEG-IFN α plus ribavirin therapy are high, health care providers should judiciously determine the clinical usefulness of these novel agents on the basis of treatment duration, anticipated viral responses, patient tolerance, financial burdens, and drug accessibility.

show abstract

Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C

Mah

Liu

Chen

et al. 2016

Journal of the Formosan Medical Association

View full text Add to dashboard Cite

show abstract

IL28B Genotype on HCV Infection in Asia

Cited by 3 publications

References 89 publications

Identification of IL-28B Genotype Modification in Hepatocytes after Living Donor Liver Transplantation by Laser Capture Microdissection and Pyrosequencing Analysis

Identification of IL-28B Genotype Modification in Hepatocytes after Living Donor Liver Transplantation by Laser Capture Microdissection and Pyrosequencing Analysis

Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa

Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C

Contact Info

Product

Resources

About